volition-nets-7
logo-nets
Our Nu.Q® NETs assay detects diseases associated with NETosis, such as sepsis.
Overview

Rapid detection of sepsis is vital.

Sepsis is the number one cause of death in hospitals worldwide. It kills an estimated 11 million people a year, which is more than cancer or coronary disease. In 2017, there were an estimated 49 million cases, with over half of all cases occurring among children and accounting for 2.9 million deaths in under-fives. Just under half of all survivors are left with psychological and/or physical effects.

Sepsis, also known as ‘blood poisoning’, is hard to identify. Initial symptoms of sepsis are difficult to distinguish from most infections and there is currently a lack of tests to diagnose it symptomatically. Without prompt treatment, it can lead to multiple organ failure and death.

Early detection and treatment of sepsis has the potential to improve survival – and improve the quality of life of survivors.  Imagine if a simple blood test could help diagnose sepsis and identify those patients more likely to deteriorate.

Our Nu.Q® NETs assay detects diseases associated with NETosis, such as sepsis. It has the potential to help doctors accurately diagnose disease and could also help predict disease severity, measure the treatment response and monitor disease progression.

This simple, low-cost, accessible, routine blood test quantifies an individual’s level of circulating H3.1 nucleosomes, a surrogate maker for NETs.  An elevated level of NETs can lead to tissue damage, and in severe cases, sepsis, organ failure and death.

0 m

Estimated 11 million deaths from sepsis worldwide each year

0 %

Risk of death increases by 7.6% for every hour of treatment delay.

The science of nets

Understanding NETs and NETosis – a recent breakthrough in medical science

volition-nets-3
Introducing Nu.Q® NETs

The immune system is comprised of many different types of white blood cell with different functions. The most abundant cells are neutrophils, which serve as the first line of defense. When they detect bacteria, viruses or fungi, these cells produce Neutrophil Extracellular Traps (NETs) – sticky webs made of long strings of nucleosomes that stop the threat from spreading around the body. This unique form of cell death is called NETosis. NETs released into the blood stream, contain nucleosomes, which can be detected by our Nu.Q® NETs assay – the only analytically validated assay to quantify the level of NETs.

Although NETs play a critical role in our normal immune response, elevated levels of NETs are a complicating factor associated with poor patient outcomes in sepsis, cancer, and a range of other diseases.

Introducing Nu.Q® NETs.

Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis. Our assay can be used to identify patients with clinically relevant elevated levels of circulating NETs and enable physicians to rapidly treat these patients.

Chromosomes and NETs are made of nucleosomes, and NETs play a pivotal role in endothelial damage and the formation of microthrombi and resultant multiorgan failure.

Our Nu.Q® NETs is the only analytically validated assay to quantify the level of NETs. It is platform agnostic so it can be adapted to any workflow/clinical setting – including central lab and point of care.

Nu.Q® NETs will support clinical decision-making, enabling physicians to act quickly, improving patient outcomes and patient management.

It is registered for use in Europe in both ELISA (Enzyme-Linked Immunosorbent Assay) and automated ChLIA (ChemiLuminescence ImmunoAssay) formats.

NETosis graphic Nov 2023
icon-microscope-blue

Simple, routine blood test

 

icon-clock-blue

Correlates with SOFA, APACHE II

icon-computer-blue

The only analytically validated assay to quantify the level of NETs

Working together.

We are working with teams at several major hospitals across Europe, undertaking studies to test our technology as a diagnostic aid for sepsis, to monitor disease progression and treatment response.

gsst

Who: St Guy’s and St Thomas’

About: Our latest trial is with Guy’s and St Thomas’ NHS Foundation Trust who are running a 500-patient study in critically unwell patients with sepsis in a real-world clinical setting. This is the first time a test to detect NETs directly has been brought to the bedside.

 

volition-discover-2
Untitled design (1)

Who: Hospice Civil de Lyon, France

About: We are working with Hospices Civil de Lyon to measure nucleosome levels using the Nu.Q® NETs assay in septic shock patients.

 

volition-capture-2
santersus logo

Who: Santersus AG

About: We are working with Santersus AG, which is developing “NucleoCapture”, a transformational technology that cleanses blood of NETs as a sepsis treatment. They used Nu.Q® NETs within an animal study to measure treatment response and have moved to their first human trial, with results due shortly.

volition-nets-3
icon-microscope-blue

Detect NETosis

 

icon-computer-blue

Predict disease severity and support risk stratification

 

icon-clock-blue

Monitor disease progression

 

“Detecting sepsis early is critical to saving lives. Sepsis is the number one cause of death in hospitals and mortality increases as much as 8% for every hour that treatment is delayed. Being able to spot those patients most at risk of sepsis using a simple blood test would be a paradigm shift in the field and could save thousands of lives every year.”
Dr Andrew Retter
Critical Care Consultant at St Guy’s and St Thomas’ NHS Foundation Trust